Xenin is a gastrointestinal hormone that reduces food intake when administered centrally and it has been hypothesized that central action of xenin participates in the regulation of whole-body metabolism. The present study was performed to address this hypothesis by investigating the central effect of xenin on the expression of genes and proteins that are involved in the regulation of lipid metabolism in white adipose tissue (WAT). Male obese ob/ob mice received intracerebroventricular (i.c.v.) injections of xenin (5 μg) twice 12 h apart. Food intake and body weight change during a 24-h period after the first injection were measured. Epididymal WAT was collected at the end of the 24-h treatment period and levels of lipid metabolism-related genes and proteins were measured. Xenin treatment caused significant reductions in food intake and body weight compared to control vehicle treatment. Levels of fatty acid synthase (FASN) protein were significantly reduced by xenin treatment, while levels of adipose triglyceride lipase (Atgl) and beta-3 adrenergic receptor (Adrb3) mRNA and phosphorylated hormone sensitive lipase (Ser 660 -pHSL and Ser 563 -pHSL) were significantly increased by xenin treatment. These findings suggest that central action of xenin causes alterations in lipid metabolism in adipose tissue toward reduced lipogenesis and increased lipolysis, possibly contributing to xenin-induced body weight reduction. Thus, enhancing central action of xenin and its downstream targets may be possible targets for the treatment of obesity by reducing the amount of stored fat in adipose tissue.
Introduction
Hormones produced by the gastrointestinal tract play a role in the regulation of whole body energy balance. Gut hormones such as cholecystokinin (CCK), peptide tyrosine tyrosine (PYY) and glucagon-like peptide-1 (GLP-1) are released into the circulation in response to nutrient ingestion, and have been implicated in the control of food intake by limiting the size of individual meals. Ghrelin on the other hand is the only orexigenic gut hormone with high plasma levels before meals (Kairupan et al., 2016) . Xenin, another gut hormone is a 25-amino acid peptide that is produced by a subset of intestinal K cells. It is secreted into the circulation in response to food ingestion, suggesting that xenin acts as an endogenous satiety factor (Anlauf et al., 2000; Feurle et al., 1992; Feurle et al., 2003) . Consistent with this assumption, both peripheral and central administrations of xenin reduce food intake in rodents and chicks (Alexiou et al., 1998; Cline et al., 2007; Cooke et al., 2009; Leckstrom et al., 2009) . Xenin reduces food intake partly through reduced gastric emptying rate without causing taste aversion (Cline et al., 2007; Kim and Mizuno, 2010b; Leckstrom et al., 2009) .
Intraperitoneal (i.p.) injection of xenin increases the number of Fos-immunoreactive cells, a marker of cell activation, in several hypothalamic nuclei and the nucleus of solitary tract of the brainstem that are known to be involved in the regulation of energy balance (Cline et al., 2007; Kim and Mizuno, 2010b; Leckstrom et al., 2009) . Extracellular signalregulated kinase (ERK) signaling pathway is also activated in hypothalamic neurons after i.p. xenin administration (Kim et al., 2016) . Moreover, feeding-suppressing effect of xenin has also been shown to be associated with hypothalamic appetite-regulating neuropeptide systems (Cooke et al., 2009; Kim and Mizuno, 2010a; Kim et al., 2014; Nandar et al., 2008; Schusdziarra et al., 2004) . These findings support the hypothesis that xenin inhibits feeding at least partly through the activation of specific cells in the central nervous system (CNS) involving the hypothalamus and the brainstem.
Although the effect of centrally administered xenin on food intake has been studied, little is known about the role of xenin in the regulation of body weight and adiposity. Feeding-suppressing effect of xenin is mediated via neurotensin receptor 1 (Ntsr1) (Kim and Mizuno, 2010a) . Ntsr1-deficient mice are characterized by hyperphagia and mild obesity, implicating the signaling through Ntsr1 in feeding and body weight regulation (Opland et al., 2013; Remaury et al., 2002) . Thus, activation of Ntsr1 by xenin may influence not only food intake but also body weight. If an overall effect of xenin is catabolic, it should promote metabolic alterations that favor increased energy utilization and/or decreased energy storage. Therefore, we hypothesized that increased central action of xenin will lead to changes in the expression of lipid metabolism-related genes and proteins in the adipose tissue toward reducing the amount of stored fat. To address this hypothesis, we examined the effect of intracerebroventricular (i.c.v.) xenin treatment on the expression levels of lipogenic and lipolytic genes and proteins in white adipose tissue (WAT) of obese mice in the present study.
Materials and methods

Animals
Male 4-month-old ob/ob mice (C57BL/6J background) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Animals were maintained under a 12:12 light/dark cycle (lights on at 0600 h) with free access to standard rodent chow pellets (Prolab RMH 3000, 4.5% fat by weight, Ralston Purina) and water throughout the experiment. All studies were approved by the Institutional Animal Care and Use Committee (University of Manitoba).
I.c.v. cannulation
Mice were anesthetized with an i.p. injection of ketamine (100 mg/kg b.w.)/xylazine (10 mg/kg b.w.). The topical anesthetic bupivacaine (1 mg/kg b.w.) was applied to the skin before making an incision. A stainless steel guide cannula (outer diameter: 0.64 mm, inner diameter: 0.33 mm) was stereotaxically implanted into the lateral ventricle with the following coordinates: 0.4 mm posterior to the bregma, 1.0 mm lateral from the midline and 1.8 mm deep to the dura in accordance with the atlas of Paxinos and Franklin (2001) . The cannula was fixed to the skull with dental cement and stainless steel screws. The mice received subcutaneous injection of buprenorphine (0.1 mg/kg b.w.) 3 times per day for 3 days post-surgery. Localization of the cannula was verified by assessing drinking behavior responses to the i.c.v. administration of angiotensin II (100 ng in 1 μl). Only mice responding with a robust drinking behavior were used for the experiment. Localization of the cannula was also confirmed at the end of the experiment by injecting the dye through the cannula and only mice showing a spread of dye in the ventricle system were included in the experiment. Of the 15 mice that underwent stereotaxic surgery, one mouse died post-surgery from an unknown reason and two mice lost cement head caps before the i.c.v. treatment experiment. One mouse (out of 12) did not show the drinking response to angiotensin II and was removed from the study. Two mice (out of 11) did not show spread of the dye in the ventricular system after dye injection and were excluded from the study.
I.c.v. xenin treatment and tissue collection
To determine if the central action of xenin reduces body weight, we examined the effect of i.c.v. administration of xenin on food intake and body weight in ob/ob mice. Ad libitum fed mice received 2 i.c.v. injections of xenin (5 μg/injection, American Peptide Co., Sunnyvale, CA, USA) at 1000 h and 2200 h. Xenin was reconstituted in artificial cerebrospinal fluid (aCSF) consisting of 124 mM NaCl, 26 mM NaHCO 3 , 5 mM KCl, 1.2 mM KH 2 PO 4 , 1.3 mM MgSO 4 , 2.4 mM CaCl 2 and 10 mM D -glucose. Control mice received two i.c.v. injections of aCSF. Drugs were injected in a total volume of 1 μl over 30 s. An injection pipe was left inside the cannula for another 30 s then removed from the cannula. Body weight and food weight were measured immediately prior to the first injection and 24 h after the first injection, and body weight change and food intake during a 24-h period were calculated. The mice were euthanized by CO 2 narcosis 12-14 h after the second injection (between 1000 h and 1200 h). Epididymal adipose tissues and skeletal muscles were collected for RNA and protein analyses.
RNA analysis
Total RNA was extracted from the tissue of each animal, cDNA was prepared, and mRNA expression levels were measured by real-time PCR using the ABI 7500 Fast thermal cycler (Applied Biosystems, Foster City, CA, USA) as described previously (Poritsanos et al., 2008) . All the gene-specific primers (Table 1) were designed with Primer Express software (Version 3.0, Applied Biosystems). Levels of mRNA were normalized to β-actin or cyclophilin mRNA levels, and were expressed as a percentage of the aCSF-treated control group. All reactions were performed in triplicates and the coefficient of variation was b 5% for each triplicate.
Western blot analysis
Tissues were lysed in protein lysis buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol and 1% Triton X-100) and supplemented with EDTA-free proteinase inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Total protein concentration was determined by Bradford assay. Proteins (20 μg) were separated using 10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes (Westran, Whatman Schleicher & Schuell, Keene, NH, USA). After blocking with 5% non-fat milk in 1 × Tris-buffered saline with 0.05% Tween 20 (TBST) for 1 h at room temperature, membranes were incubated overnight at 4°C in primary antibodies for total hormone sensitive lipase ( and α-tubulin (#sc-8035, 1:1000, Santa Cruz Biotechnology) diluted in blocking buffer, followed by washing in TBST. Appropriate horseradish peroxidase-conjugated secondary antibody was used at 1:10,000 dilution and incubated for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence system (Advansta Inc, Menlo Park, CA, USA). Densitometry of the bands on autoradiography film was analyzed using Quantity One software (Bio-Rad, Hercules, CA, USA). Signal intensity of Ser 660 -pHSL and Ser
563
-pHSL was normalized to tHSL signal intensity. Signal intensity of other proteins was normalized to α-tubulin signal intensity. Levels of protein were expressed as a percentage of the aCSF-treated control group.
Blood chemistry
Serum free fatty acids (FFA) and glycerol levels were determined by colorimetric assay with commercial kits (SFA-1, Zen-Bio, Research Triangle Park, NC, USA and 10,010,755, Cayman Chemical Co., Ann Arbor, MI, USA, respectively).
Statistical analysis
Data are presented as means ± standard error of the mean (S.E.M.). Comparisons between 2 groups were performed by Student's t-test (for parametric data) or Wilcoxon test (for nonparametric data). In all cases, differences were taken to be significant if P-values were below 0.05.
Results
3.1. Effect of i.c.v. xenin treatment on food intake, body weight, and serum levels of FFA and glycerol in ob/ob mice I.c.v. xenin treatment significantly reduced 24-h food intake by 33.0% compared to the control aCSF treatment in obese ob/ob mice (P b 0.05 by Student's t-test, Fig. 1A ). Body weights before xenin treatment were indistinguishable between the groups (control: 61.1 ± 1.4 g, xenin: 58.5 ± 0.9 g, P = 0.13 by Student's t-test). At the end of the 24-h treatment period, xenin-treated mice had significantly smaller body weight compared to the control mice (control: 61.4 ± 1.2 g, xenin: 57.6 ± 0.7 g, P b 0.05 by Student's t-test). Body weight change during the 24-h treatment period was significantly smaller in xenin-treated mice compared to the control mice (P b 0.05 by Student's t-test, Fig. 1B ). Xenin treatment did not cause significant changes in serum FFA (P = 0.38 by Student's t-test, Fig. 1C ) and glycerol levels (P = 0.62 by Student's t-test, Fig. 1D ).
Effect of i.c.v. xenin treatment on the expression of lipid metabolism-related genes in white adipose tissue and skeletal muscle
Xenin treatment significantly increased Atgl mRNA levels in WAT of obese ob/ob mice by 52.1% compared to the control aCSF treatment (P b 0.05 by Student's t-test) without significant changes in hormone 
a Forward primer (F) and reverse primer (R). sensitive lipase (Lipe) mRNA levels (P = 0.22 by Student's t-test, Fig. 2A ). Xenin treatment also significantly increased beta-3 adrenergic receptor (Adrb3) mRNA levels by 76.8% in WAT compared to the control aCSF treatment (P b 0.05 by Student's t-test, Fig. 2A ). Levels of acetylCoA carboxylase 1 (Acc1, P = 0.31 by Wilcoxon test), Fasn (P = 0.73 by Student's t-test) and stearoyl-CoA desaturase 1 (Scd1, P = 0.47 by Student's t-test) mRNA were indistinguishable between control and xenin-treated mice (Fig. 2B) . I.c.v. xenin treatment did not cause significant changes in uncoupling protein 1 (Ucp1, P = 0.67 by Student's ttest), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Ppargc1a, P = 0.66 by Student's t-test) and PR domain zinc finger protein 16 (Prdm16, P = 0.60 by Student's t-test) mRNA levels in WAT (Fig. 2C) . Xenin treatment significantly increased lipoprotein lipase (Lpl) mRNA levels by 155.6% in skeletal muscle compared to aCSF treatment (P b 0.05 by Wilcoxon test), while it did not alter Ucp3 mRNA levels (P = 0.33 by Student's t-test, Fig. 2D) 
Effect of i.c.v. xenin treatment on the expression of lipid metabolism-related proteins in white adipose tissue
Xenin treatment significantly increased phosphorylation of HSL at Ser 660 and at Ser 563 in WAT by 30.3% and 56.0% compared to the control aCSF treatment, respectively (P b 0.05 by Student's t-test, Fig. 3A -C) without significant changes in ATGL (P = 0.97 by Student's t-test, Fig. 3A , D), perilipin (P = 0.54 by Student's t-test, Fig. 3A , E) and CGI-58 (P = 0.83 by Student's t-test, Fig. 3A, F) protein levels. Levels of FASN protein in WAT were 41.5% lower in xenintreated ob/ob mice compared to aCSF-treated control ob/ob mice (P b 0.005 by Student's t-test, Fig. 4 ).
Discussion
Studies have demonstrated that xenin reduces food intake, increases insulin secretion and reduces blood glucose levels. Thus, it has been proposed that increased secretion of xenin after a meal contributes to the termination of feeding and reduction of postprandial glycemia. Anorectic effect of xenin is mediated via Ntsr1 and Ntsr1-deficiency is associated with hyperphagia and mild obesity in mice (Kim and Mizuno, 2010a; Opland et al., 2013; Remaury et al., 2002) . These findings raised the possibility that central action of xenin reduces body weight through the activation of Ntsr1. However, the role of xenin in the regulation of whole body metabolism is obscure. The present study demonstrates for the first time that the short-term i.c.v. treatment with xenin reduces food intake and body weight in obese ob/ob mice, increasing the prospect that enhanced central action of xenin and its downstream signaling may ameliorate obesity.
We have previously demonstrated that a single i.p. injection of xenin reduced food intake in leptin-deficient ob/ob mice (Leckstrom et al., 2009) . Similarly, i.c.v. xenin treatment caused reductions in food intake and body weight in ob/ob mice in the present study. These findings suggest that xenin reduces food intake and body weight through a mechanism that is independent of leptin action. Leptin deficiency is rare but resistance to the metabolic effect of leptin is common in human obesity. Anorectic effect of xenin is preserved in leptin-resistant obese agouti mice and sensitivity to the blood glucose lowering effect of xenin remains intact in leptin-resistant high fat diet-induced obese mice (Gault et al., 2015; Leckstrom et al., 2009; Martin et al., 2016; Parthsarathy et al., 2016) . Taken together, these findings illustrate the possible beneficial effects of enhanced central action of xenin on obesity including leptin resistant obesity through a leptin-independent mechanism.
Xenin-induced body weight reduction might be due to alterations in energy substrate partitioning. Expression of lipid metabolism-related genes and proteins in WAT were altered by i.c.v. xenin treatment. Expression of lipolytic markers (i.e. Atgl mRNA, Ser 660 -pHSL and Ser 563 -pHSL) was increased, while expression of lipogenic marker (i.e. FASN) was reduced in WAT of xenin-treated mice. WAT is innervated by the sympathetic nervous system (SNS) and activation of the SNS triggers intracellular signaling events that stimulate lipolysis in WAT via beta-3 adrenergic receptors. Adrb3 mRNA expression was upregulated in WAT of xenin-treated mice. These data support the possibility that central action of xenin increases adipose tissue lipolysis by increasing sympathetic outflow toward WAT and reduces lipogenesis, contributing to the reduction of body weight. Xenin treatment failed to increase serum levels of FFA and glycerol. Although one-day xenin treatment (two i.c.v. injections) caused a significant increase in the expression of lipolytic genes and proteins in WAT, it might not be enough to cause measurable changes in serum FFA and glycerol levels. Thus, changes in gene and protein expression may represent early stage changes toward increased lipolysis and subsequent increase in serum levels of FFA and glycerol. It is also possible that the additive effect of a subtle increase in lipolysis and reduced lipogenesis might be enough to cause the significant reduction in body weight gain in xenin-treated mice without significant changes in serum FFA and glycerol levels.
Increasing evidence suggests that brown and beige fat cells play a role in the regulation of metabolism. Increased amount and activity of these thermogenic cells leads to increased energy expenditure and reduced adiposity and body weight (Wu et al., 2013) . Expression of markers of browning/beiging (i.e. Ucp1, Ppargc1a and Prdm16 mRNA) in WAT was not influenced by i.c.v. xenin treatment in the present study. Thus, it is unlikely that increased thermogenic capacity of WAT contributes to the xenin-induced weight reduction. In addition to the increased adipose tissue lipolysis, increased uptake and oxidation of fatty acids by other metabolically active tissues may contribute to body weight reduction. LPL promotes hydrolysis of chylomicron-and very low density lipoprotein (VLDL)-associated triacylglycerides and facilitates fatty acids uptake by tissues, while UCP3 is closely tied to fatty acid metabolism. We found that Lpl mRNA levels in skeletal muscle were increased in xenin-treated mice. However, xenin treatment did not cause a significant change in Ucp3 mRNA levels in skeletal muscle. This is possibly due to the short duration of xenin treatment that might not be long enough to produce significant changes in fat oxidation in skeletal muscle in the present study. Collectively, these findings suggest that central action of xenin causes alterations in lipid metabolism in adipose tissue toward reduced lipogenesis and increased lipolysis and increased lipid uptake by skeletal muscle, possibly contributing to xenin-induced body weight reduction. Intriguingly, we found that sub-chronic xenin treatment (once daily i.p. injections for 10 days) in normal lean C57BL/6 mice resulted in reduced body weight compared to both control saline treated group and pair feeding group (ER Kim and TM Mizuno, unpublished data) . Thus, i.c.v. xenin-induced reduction of body weight gain and alterations in the expression of lipid metabolism-related genes and proteins in WAT and skeletal muscle are possibly independent of changes in food intake in the present study.
Peripheral administration of xenin increases the levels of hypothalamic c-fos mRNA and the number of Fos-immunoreactive cells in several hypothalamic nuclei that are known to be involved in the regulation of energy balance (Cline et al., 2007; Leckstrom et al., 2009) . Xenin treatment also increases the number of phopho-ERK1/2 (pERK1/2)-positive cells in the hypothalamus (Kim et al., 2016) . Thus, metabolic actions of xenin may be mediated through the activation of specific hypothalamic cells. Moreover, feeding-suppressing effect of xenin has been shown to be associated with hypothalamic appetite-regulating neuropeptide systems (Cooke et al., 2009; Kim and Mizuno, 2010a; Kim et al., 2014; Nandar et al., 2008; Schusdziarra et al., 2004) . When naloxone, an opioid receptor antagonist, was injected i.c.v. at a subthreshold dose, xenin (i.c.v.)-induced anorexia was augmented and i.c.v. co-injection of low doses of naloxone and xenin showed a synergistic effect on food intake (Schusdziarra et al., 2004) . I.c.v. pretreatment with corticotrophinreleasing hormone (CRH) antagonist negated xenin (i.c.v.)-induced feeding suppression (Cooke et al., 2009) . Moreover, anorexigenic effect of xenin was abolished or attenuated in mice lacking Ntsr1 or type I interleukin 1 receptor (IL-1RI) (Kim and Mizuno, 2010a; Kim et al., 2014) . These findings suggest that endogenous opioid system may counter the anorectic action of xenin and xenin reduces food intake by activating signaling pathways that involve CRH, Ntsr1 and IL-1RI. Interestingly, CRH and IL-1 have been shown to be involved in the regulation of WAT lipolysis through the activation of the SNS (Berkenbosch et al., 1987; Egawa et al., 1990; Sapolsky et al., 1987; Toriya et al., 2010) . Thus, xenin-induced alterations in the expression of lipid metabolismrelated genes and proteins in WAT may also be mediated through these CNS-SNS signaling pathways. This possibility, however, needs to be further investigated.
Xenin is present in cerebrospinal fluid (CSF) and there is a positive correlation between serum xenin levels and CSF xenin levels, suggesting a possible transportation of xenin and degraded products of xenin from blood to CSF (van de Sande-Lee et al., 2013). Xenin is also present in the hypothalamus at a low level (Hamscher et al., 1995) . Hence, it is possible that both peripherally produced xenin and centrally produced xenin act on specific target cells in the CNS, causing alterations in food intake and whole-body metabolism. It has been reported that plasma half-life of xenin is b 4 h and xenin is quickly degraded into smaller fragments, some of which still retain biological activity (Feurle et al., 1996; Feurle et al., 2002; Hamscher et al., 1995; Martin et al., 2012; Martin et al., 2016; Taylor et al., 2010) . The C-terminal octapeptide fragment of xenin (xenin 18-25) has biological activity similar to that of native xenin Martin et al., 2014; Silvestre et al., 2003) . Considering the expected short half-life of xenin in the cerebrospinal fluid, it is likely that central action of both native xenin and xenin 18-25 contributed to the changes in the expression of lipid metabolism-related genes and proteins in WAT and skeletal muscle in the present study.
Our study examined the effect of short-term (24 h) xenin treatment on body weight and it is unclear whether or not the beneficial weightreducing effect of xenin can last for a longer period of time. Recent studies reported that sub-chronic treatment with xenin or its analogue that is less vulnerable to enzymatic degradation failed to reduce body weight in normal lean and obese mice (Gault et al., 2015; Martin et al., 2016; Parthsarathy et al., 2016) . These findings do not support the feasibility of using xenin and its analogue in the treatment of obesity. However, all injections were administered via peripheral routes in these studies and no study examined the effect of central administration of xenin for an extended period of time on body weight. Thus, sub-chronic central treatment with xenin or xenin analogues needs to be performed in future experiments. Additionally, there are well-documented literatures indicating that full-length xenin, xenin 18-25 and their analogues play a role in the regulation of glucose homeostasis by increasing pancreatic insulin secretion and countering glucagon action (Gault et al., 2015; Martin et al., 2012; Martin et al., 2016; Martin et al., 2014; Parthsarathy et al., 2016; Silvestre et al., 2003; Taylor et al., 2010; Wice et al., 2012; Wice et al., 2010) . It is crucial to determine if central action of these peptides contributes to the glucose-lowering effect in future experiments.
Conclusion
The present study provides the evidence that central action of xenin causes a reduction in body weight in obese mice that is accompanied by alterations in gene and protein expression in WAT toward reduced lipogenesis and increased lipolysis, possibly contributing to xenin-induced body weight reduction. Therefore, enhancing central action of xenin and its downstream targets may constitute a potentially effective strategy for the treatment of obesity by reducing the amount of stored fat in adipose tissue. Further studies may be necessary to determine the effect of a long-term central xenin treatment on lipid metabolism and body weight in obesity.
